Raymond W. Cohen
Raymond W. Cohen's purchase track record
Raymond W. Cohen has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 3/26/2026 | KMTS | $200K | +14.7% | +30.9% | +18.9% |
| 3/7/2025 | KMTS | $289K | -1.4% | -19.0% | +12.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
BofA Lowers RxSight Target to $5.5 Amid Growth Headwinds. Bank of America analysts say RxSight's potential for utilization growth is limited by structural and competitive challenges. They lowered the price target to $5.50 and keep an underperform rating. The stock is trading near its 52‑week low and close to a support level of $4.88.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
InspireMD (NSPR) noted in pre‑market health‑care stock moves. NSPR was listed among twelve health‑care companies showing price action in Friday’s pre‑market session, according to Benzinga. The move comes while the stock’s RSI is low at 25.7 and it is near its $0.70 support level, suggesting continued pressure. Such activity may reflect renewed trader attention despite the broader market context.
Transaction History
| KMTS | ▼ Sell | Open Market | 3,330 | $98K | 9/30/2026 | View on chart |
| KMTS | ▲ Buy | Grant | 7,217 | — | 9/9/2026 | View on chart |
| RXST | ▲ Buy | Grant | 30,864 | — | 6/17/2026 | View on chart |
| KMTS | ▲ Buy | Open Market | 10,000 | $200K | 3/26/2026 | View on chart |
| NSPR | ▲ Buy | Grant | 44,030 | $0 | 1/14/2026 | View on chart |
| KMTS | ▲ Buy | Grant | 10,909 | — | 9/4/2025 | View on chart |
| RXST | ▲ Buy | Grant | 35,668 | $0 | 7/31/2025 | View on chart |
| KMTS | ▲ Buy | Grant | 12,994 | — | 7/24/2025 | View on chart |
| KMTS | ▲ Buy | Open Market | 17,000 | $289K | 3/7/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
Analyst Reiterates Rating on Kestra Medical Technologies with $32 Target
BTIG has reiterated its positive view on Kestra Medical Technologies, keeping a $32 price target on the stock. The reaffirmation comes as broader medical device peers report mixed quarterly results: Phreesia fell short of Q2 earnings and revenue estimates, while Medtronic beat on both lines. These peer results provide context for the medical device sector backdrop against which Kestra is being evaluated.
Analyst Reiterates Rating on Kestra Medical Technologies with $32 Target. BTIG has reiterated its positive view on Kestra Medical Technologies, keeping a $32 price target on the stock. The reaffirmation comes as broader medical device peers report mixed quarterly results: Phreesia fell short of Q2 earnings and revenue estimates, while Medtronic beat on both lines. These peer results provide context for the medical device sector backdrop against which Kestra is being evaluated.